Lilly's amylin combo raises the bar, and the stakes, for obesity drug developers Phase 2b data for EloraTZP suggest the next gains in obesity will come from stacking hormone pathways, and that tolerability may decide who wins. Written byAndrea Corona

Lilly's amylin combo raises the bar, and the stakes, for obesity drug developers Phase 2b data for EloraTZP suggest the next gains in obesity will come from stacking hormone pathways, and that tolerability may decide who wins. Written byAndrea Corona https://www.drugdiscoverynews.com/lilly-s-amylin-combo-raises-the-bar-and-the-stakes-for-obesity-drug-developers-17564 Eli Lilly's latest obesity readout is more than a win for one program. By showing that an amylin agonist added to tirzepatide can push weight loss well past what tirzepatide achieves alone, the company has given drug developers a clearer picture of where the field is heading and what it will take to compete there. In the 48-week Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes, the top dose of EloraTZP, which pairs the selective amylin receptor agonist eloralintide with tirzepatide, cut body weight by 23.3 percent. Tirzepatide 15 mg alone delivered 14.8 percent, and eloralintide alone up to 12.3 percent. A1C fell 2.9 percentage points on the combination versus 2.4 on tirzepatide.